论文部分内容阅读
一、亲属及无关供者的移植:治疗恶性血液病的结果 应用异基因造血干细胞(HSCT)治疗骨髓疾病(例如:白血病和B细胞恶性肿瘤),传统的预处理方法包括大剂量的化疗合并(或不合并)全身照射(TBI)。这是基于最初的假说,认为骨髓清除性的大剂量化疗和TBI能够克服供者的免疫反应同时消灭现有疾病。然而,由于强烈的预处理对非骨髓器官(如肠、肝、肺脏、心脏)的毒性作用,传统的大剂量移植被限定于年轻(50—55岁以下)并且一般状况好的患者。由于血液系统肿
First, the transfer of relatives and unrelated donors: the results of the treatment of hematologic malignancies Allogeneic hematopoietic stem cells (HSCT) treatment of bone marrow diseases (such as: leukemia and B cell malignancies), the traditional pre-treatment methods include high-dose chemotherapy combined Or uncombined) Total body irradiation (TBI). This is based on the initial hypothesis that high bone marrow clearance chemotherapy and TBI can overcome the donor’s immune response while eliminating the existing disease. However, due to the toxic effects of intense pretreatment on non-myeloid organs such as the intestine, liver, lung, and heart, conventional high-dose grafting is limited to patients younger than 50-55 years and generally in good condition. Because of the hematogenous system